Thomas W. Ackermann is a Partner of Mandelbaum Barrett PC practicing in the Corporate Law and Business Transactions and Taxation practice groups since 2003. Tom has an LL.M. in Taxation from New York University School of Law and he is also a licensed Certified Public Accountant in the State of New Jersey.
Tom utilizes his LL.M. in Taxation and more than 30 years of experience as a tax and corporate attorney and Certified Public Accountant to develop creative solutions to complex tax, estate planning and business issues faced by the firm’s clients. Tom’s practice focuses on advising and representing the owners of closely-held corporations, limited liability companies and partnerships with all aspects of merger and acquisition transactions and in providing tax, estate and business succession planning services.

Tom’s multi-disciplined background enables him to function as outside legal counsel and advise business owners on day-to-day legal and business management matters, including as a member of the board, and ultimately on exit strategies for the transfer of their ownership interests to the next generation, third-party strategic purchasers and private equity investors.

In addition to tax planning and the drafting of sophisticated estate, buy-sale and business succession planning documents, Tom’s primary area of concentration involves negotiating and drafting of business agreements for mergers, stock or membership interest purchases, asset acquisitions, reorganizations, and other business transactions.

Tom’s prior experience includes being a partner in several other mid-sized New Jersey law firms and initially after graduating from law school, Tom was a senior tax manager at the New York City office of a Big 5 accounting firm.

  • New Jersey State Bar Association
  • New Jersey Society of Certified Public Accountants

  • State of New Jersey
  • U.S. Tax Court
  • Certified Public Accountant, New Jersey

  • New York University School of Law, LL.M. in Taxation
  • New York Law School, J.D.
  • Rutgers College, B.A.

Healthcare Alert: Eli Lilly Dismisses Lawsuit Against Mandelbaum Barrett PC’s Pharmacy Client in Florida

April 30, 2024

In the summer and fall of 2023, certain pharmaceutical companies, such as Novo Nordisk (Ozempic, Wegovy, and Rybelsus) and Eli Lilly (Mounjaro), filed lawsuits across the country against medical spas and wellness centers, compounding facilities, and pharmacies that dispense drugs containing the active pharmaceutical ingredient semaglutide (Novo Nordisk) or tirzepatide (Eli Lilly). These drugs have […]